Archive for the ‘Bone repair’ Category

Bone irradiated and then placed back into body

Posted 22 Jul 2010 — by James Street
Category Bone repair

Wednesday, July 21, 2010

When 6-year-old Darya Egorova was first diagnosed with bone cancer – doctors told her parents there was a good chance they would have to amputate her leg. But thanks to a revolutionary new procedure — that took less than three hours — the Russian girl is cancer free, the Daily Mail reported.

Darya was diagnosed by Russian doctors who told her parents they had very few treatment options that would allow her to stay mobile. Her parents were devastated, but a Russian cancer charity, Grant Life, changed all that, when they volunteered to help pay for a new procedure in Britain.

Darya and her parents traveled to the Harley Street Clinic in London where doctors removed 4 inches of cancer-ridden bone from her right shin including a 2-inch tumor. The bone was then blasted with very high doses of radiotherapy and reinserted back into her leg.

Two days after the pioneering surgery, Darya attempted to walk with crutches, and left hospital within a week. Now, one year later, she’s standing tall, dancing, playing sports and enjoying school.

Doctors said over the next two years, the healthy bone will grow through the dead bone, and bring it back to life.

“Given the surgical options my daughter was offered outside the U.K., what surgeons have done is truly a miracle,” Darya’s mom, Irina, told the newspaper.

Replacement Bones, Grown to Order in the Lab

Posted 30 Mar 2010 — by James Street
Category Bone repair
By ANNE EISENBERG New York Times

IF a lover breaks your heart, tissue engineers can’t fix it. But if sticks and stones break your bones, scientists may be able to grow custom-size replacements.

Gordana Vunjak-Novakovic, a professor of biomedical engineering at Columbia University, has solved one of many problems on the way to successful bone implants: how to grow new bones in the anatomical shape of the original.

Dr. Vunjak-Novakovic and her research team have created and nourished two small bones from scratch in their laboratory. The new bones, part of a joint at the back of the jaw, were created with human stem cells. The shape is based on digital images of undamaged bones.

Tissue-engineered bones have many implications, according to a leading figure in the field, Dr. Charles A. Vacanti, director of the laboratories for tissue engineering and regenerative medicine at the Brigham and Women’s Hospital in Boston. He has no connection to the Columbia work. “If your imaging equipment has sufficient high resolution, you can construct virtually any intricate shape you want — for example, the middle ear bone, creating an exact duplicate,” he said. “It’s a splendid example of tissue engineering at its best.”

Engineered bones are being tested in animals and in a few people, and may be common in operating rooms within a decade, said Rosemarie Hunziker, a program officer at the National Institute of Biomedical Imaging and Bioengineering, which sponsors research in the field, including that at Columbia.

Many businesses, including Osiris Therapeutics and Pervasis Therapeutics are forming around tissue engineering techniques. (Pervasis, for instance, is creating blood vessel linings.)

“It’s a field that is attracting much interest from venture capitalists,” said Robert Langer, a professor at M.I.T. Dr. Langer has more than 750 patents issued or pending in tissue engineering and drug delivery systems, and is an adviser to many companies that have started businesses based on his work.

Scott Hollister, a professor at the University of Michigan, Ann Arbor, is a co-founder of Tissue Regeneration Systems, a company that is commercializing technology his group is developing for skeletal reconstruction in the face, spine and extremities.

Dr. Vunjak-Novakovic, who has filed a patent application through Columbia, said that her lab’s work had attracted considerable interest from investors, but that it was too soon to talk about commercial applications. “We are starting studies with large animals that will establish safety and feasibility before commercialization, “she said.

Dr. Vunjak-Novakovic, Dr. Warren L. Grayson and other members of the team used digital images of the joint to guide a machine that carved a three-dimensional replica, called a scaffold, from cleansed bone material. The team turned the bare scaffold into living tissue by putting it into a chamber molded to its exact shape, and adding human cells, typically isolated from bone marrow or liposuctioned fat. A steady source of oxygen, growth hormones, sugar and other nutrients was piped into the chamber, or bioreactor, so the bone would flourish.

“The cells grow rapidly,” Dr. Vunjak-Novakovic said. “They don’t know whether they are in the body or in a culture. They only sense the signals.”

Traditional bone grafts are typically harvested from other parts of the body, often a traumatic step, or made of materials like titanium that aren’t always compatible with host bones or cause inflammation, said Dr. Francis Y. Lee, a professor of clinical orthopedic surgery at Columbia’s College of Physicians and Surgeons. Dr. Lee also has no connection to Dr. Vunjak-Novakovic’s work.

“If we have an anatomically matching scaffold that can host bone cells,” Dr. Lee said, “this will provide a new way of reconstructing bone and cartilage defects.”

The design of the bioreactor is ingenious, said Dr. Vacanti of Boston, because it allows sources of nourishment and other fluids to permeate the pores of the scaffold as new bone grows within the pores. Often, cells make tissue mainly on the outside of a scaffold, while cells inside tend to die. But Dr. Vunjak-Novakovic’s bioreactor permits close observation and control of additives by the research team. “They can direct the flow and monitor the effect on the development of tissue,” Dr. Vacanti said.

PROFESSOR Hollister at Michigan is also working on creating bones of a jaw joint. But instead of using a bioreactor to grow them, he plans to use the human body as the incubator. The scaffold for the new bone, designed from a CT scan and printed directly using a laser system, is filled with cells from bone marrow or fat that are taken from the patient to prevent immune-system reactions. “Then we will let the patient’s body naturally heal and reconstruct the tissue as the implant is resorbed by the body,” he said.

Many of the components to generate good bones are in place, said David L. Kaplan, professor and chairman of the department of biomedical engineering at Tufts University. “The technology is here,” he said, “to control the size, shape and functional features of human tissue in the lab.”

The complex problems of keeping tissue alive and integrated when implanted in the body are also well on their way to being solved, Dr. Hunziker said. “We are starting to put the pieces of the puzzle together in various combinations to generate good bone,” she said, “and it’s all going to come together in a reasonable amount of time.”

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Posted 15 Mar 2010 — by James Street
Category Bone repair, Human osteosarcoma research

15. March 2010 06:35

For the localized treatment of tumors

Bone implants with the ability to carry chemotherapeutical drugs in conception in CICECO

Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential “anti-tumor” drugs coated by nanocapsules.

The osteosarcoma is the most common malignant primary bone tumor. Its major incidence is in children and youngsters and usually involves the amputation of arms and legs. The treatment for this type of tumor implies chemotherapy, followed by the surgical removal of the affected tissue with a safety area, in order to avoid the tumor’s reappearance. This area is then filled with a bone or synthetic biomaterial implant.

Considering how important it is to avoid repeating new chemo or radiotherapy treatments in these cases when neutralizing possible residual focus, 11 researchers from the Universities of Aveiro and Coimbra intend to develop an implant which can contain chemotherapeutical agents of specific ranges of action, and also release these components in a controlled manner for a specific and adequate period of time.

“The bone implants we are studying will serve as a support and releasing agent of capsulated drugs in a ciclodextrin nanocapsule. We are currently experimenting with an active molecule with anti-cancer properties specifically directed to osteosarcomas. Nevertheless, it is intended to broaden its application to other types of cancer“.

For this person, and as explained by Prof. Rui Correia, project coordinator, there is the need to proceed with the study of its mechanic and biological characteristics. “When we develop projects for these purposes, we must bear in mind their mechanic resistance, as well as other characteristics which must be taken in consideration when performing its implant in the bone. In this specific case, we are working with porous supports that contain a silica gel, manipulated to function both as a nanocapsule deposit and releaser. Its physical form will vary according to the bone area to fill.

The gel matrix will receive the anti-tumor compost (cisplatin and metallic composts), capsulated at a molecular level with ciclodextrin, coloured gello capsules which are nothing more and nothing less that sugar rings.

Prof. Ana Gil explains this innovative technique:

“A subgroup within our team, lead by researcher Susana Braga, is by the one hand, developing new metallic composts with a therapeutic potential and, by the other hand, promoting its capsulation in ciclodextrins. The use of the ciclodextrin on the coating of the medicinal molecule increases the efficiency of the drug and reduces the necessary amount. To work at a nanometric scale allows us to improve the properties, both concerning its solubility and its range of activity, allowing us to make it more specific”.

The nanocapsule protects the therapeutic agent from the contact with proteins which are irrelevant to the treatment and makes its located application simpler. The use of ciclodextrins as nanocapsules should protect the organism from the expected high toxicity of the new agents to the healthy cells.

This project, financed by the foundation for the Science and Technology, also presents an innovative aspect in what concerns the study of the metabolic effects of the new compounds (capsulated or not) on the human osteosarcoma cells, as explained by the researcher: “It is important to know the response of the cancer cells to the drugs, in order to be able to adjust and adapt the drug’s nature and dosage, for an effective treatment. These studies use the spectroscopy of the RMN- Magnetic Nuclear Resonance in the characterization of the cells’ metabolic profile and the application of adequate statistic treatments, which help identifying specific metabolic changes and their relation with the patterns of cellular death”.

With the drug in nanocapsules, there will be two types of implants to choose from: permanent titanium and biodegradable (for regenerative purposes) implants. The differences between these two are clarified by Prof. Rui Correia: “The porous supports which will allow the introduction of a chemic component in the organism are conceived from two types of biomaterials: a bio-stable one (non-degradable and biocompatible) and a polymeric, with biodegradable characteristics. The first one will be used in cases where there is a lack of ability to regenerate the bone tissue and the second in situations where there is the probability of a full natural recovery of the bone. In this last case the implant will be absorbed and progressively replaced by the natural bone”.

Besides the microstructural analysis, the researchers are proceeding with mechanic, physics and chemistry and in vitro rehearsals. There will also be performed metabolomics essays with cellular cultures which are subjected to the therapeutic agents, either molecularly encapsulated or not.

SOURCE Research Centre in Ceramic Material and Composites

New Material Mimics Bone To Create Better Biomedical Implants

Posted 24 Feb 2010 — by James Street
Category Bone repair

17 Feb 2010

A “metal foam” that has a similar elasticity to bone could mean a new generation of biomedical implants that would avoid bone rejection that often results from more rigid implant materials, such as titanium. Researchers at North Carolina State University have developed the metal foam, which is even lighter than solid aluminum and can be made of 100 percent steel or a combination of steel and aluminum.

In a new paper, researchers have reported recent findings that, in addition to the extraordinary high-energy absorption capability and light weight of their novel composite foams, the “modulus of elasticity” of the foam is very similar to that of bone. Modulus of elasticity measures a material’s ability to deform when pressure is applied and then return to its original shape when pressure is removed. The rough surface of the foam would also foster bone growth into the implant, improving the strength of implant.

Modulus of elasticity, which is measured in gigapascals (GPa), is extremely important for biomedical implants, explains Dr. Afsaneh Rabiei, an associate professor of mechanical and aerospace engineering and an associate faculty member of biomedical engineering at NC State and co-author of the paper.

“When an orthopedic or dental implant is placed in the body to replace a bone or a part of a bone, it needs to handle the loads in the same way as its surrounding bone,” Rabiei says. “If the modulus of elasticity of the implant is too much bigger than the bone, the implant will take over the load bearing and the surrounding bone will start to die. This will cause the loosening of the implant and eventually ends in failure. This is known as “‘stress shielding.’” When this happens, the patient will need a revision surgery to replace the implant. Our composite foam can be a perfect match as an implant to prevent stress shielding,” Rabiei explains.

To give an idea of the difference between the modulus of elasticity of bone and that of traditional implants, bone has a modulus of between 10 and 30 GPa – while titanium has a modulus of approximately 100 GPa. The new composite foam has a modulus that is consistent with bone, and is also relatively light because it is porous.

The rough surface of the metal foam, Rabiei says, “will bond well with the new bone formed around it and let the body build inside its surface porosities. This will increase the mechanical stability and strength of the implant inside the body.”

The research, “Evaluation of modulus of elasticity of composite metal foams by experimental and numerical techniques,” was funded by the National Science Foundation and will be published in the March issue of Materials Science and Engineering A. The research was co-authored by Rabiei and former NC State Ph.D. student L. Vendra.

Source:
Matt Shipman
North Carolina State University


Article URL: http://www.medicalnewstoday.com/articles/179401.php

Also Appears In:  Bones / Orthopaedics,